Drugs / ASP7517
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04837196 | Nov 2021 → Jun 2024 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04079296 | Sep 2019 → Apr 2023 | acute myeloid leukemia, myelodysplastic syndrome | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04079296 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT04079296 ↗ |
| Target | WT1 | “encoding target WT-1” NCT04079296 ↗ |